Vesugen (Lys-Glu-Asp, vascular bioregulator)
Khavinson tripeptide positioned as the synthetic vascular bioregulator paired with Ventfort.
At a glance
What it is: Khavinson tripeptide positioned as the synthetic vascular bioregulator paired with Ventfort..
Primary research applications:
- Vascular-system support research (Khavinson framework)
- Cardiovascular-aging discussion within the originating tradition
Editorial summary: Vesugen is the synthetic short-peptide vascular bioregulator in the Khavinson cytogen program — a tripeptide of Lys-Glu-Asp paired conceptually with the Ventfort cytomedin. Same evidence pattern as the rest of the family.
- Class / structure
- Tripeptide (Lys-Glu-Asp) — Khavinson cytogen
- Half-life
- Very short systemic half-life
- First described
- Khavinson group, post-2000 cytogen program
- Regulatory status
- Sold as a supplement; not FDA-approved
What is Vesugen?
Vesugen is a tripeptide (Lys-Glu-Asp) bioregulator positioned within the Khavinson framework as supporting vascular and endothelial function.
Discovery and development
Vesugen is the synthetic short-peptide complement to the older Ventfort cytomedin in the Khavinson framework. Both are positioned as vascular bioregulators; Vesugen represents the more recent cytogen (defined-sequence short peptide) approach within the broader bioregulator program.
Mechanism of action
Khavinson-framework mechanistic claims about tissue-specific direct signaling apply; independent Western validation is limited.[1]
Pharmacokinetics
Very short plasma half-life consistent with the Khavinson short-peptide family.
What the research shows
The peer-reviewed literature on Vesugen is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Supports vascular and endothelial function | Khavinson framework hypothesis | Uncertain |
| Has independent Western cardiovascular-outcomes evidence | Limited | Uncertain |
Reported user experiences
How the research describes administration
Oral capsules in cyclic regimens within the Khavinson product line.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Vesugen is the synthetic short-peptide vascular entry in the Khavinson program. Conceptually interesting within the framework, real research lineage, but the Western evidence base has not been built for individual claims about this compound at clinical-grade levels.
Frequently asked questions
How does Vesugen differ from Ventfort?
Both are vascular bioregulators in the Khavinson framework. Ventfort is the older cytomedin (tissue-extract mixture); Vesugen is the synthetic short peptide (Lys-Glu-Asp) intended to capture similar tissue-specific signaling in a defined molecular form.
References
- Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12422308/
- Khavinson VK, Linkova NS. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2020;10:34-45. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+vesugen